Mineralys Therapeutics Inc
Company Profile
Business description
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Contact
150 North Radnor Chester Road
Suite F200
RadnorPA19087
USAT: +1 888 378-6240
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
76
Stocks News & Analysis
stocks
Why great earnings haven't been good enough for AI hardware stocks
stocks
Fair Value increased for Big 4 bank after earnings
stocks
Chart of the Week: Why ASX tech is poised for a comeback
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,353.00 | 37.50 | -0.40% |
| CAC 40 | 8,674.94 | 40.00 | -0.46% |
| DAX 40 | 26,331.07 | 60.35 | -0.23% |
| Dow JONES (US) | 53,770.27 | 21.58 | -0.04% |
| FTSE 100 | 10,833.15 | 11.04 | -0.10% |
| HKSE | 25,436.37 | 3.80 | -0.01% |
| NASDAQ | 26,588.49 | 143.04 | 0.54% |
| Nikkei 225 | 68,683.43 | 1,159.37 | 1.72% |
| NZX 50 Index | 13,812.70 | 75.04 | 0.55% |
| S&P 500 | 7,748.50 | 20.30 | 0.26% |
| S&P/ASX 200 | 9,157.90 | 35.00 | -0.38% |
| SSE Composite Index | 3,963.15 | 16.48 | 0.42% |